|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury显示文摘The outbreak of the 2019-nCoV infection began in December 2019 in Wuhan,Hubei province,and rapidly spread to many provinces in China as well as other countries.Here we report the epidemiological,clinical,laboratory,and radiological characteristics,as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen,China.All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS).The most common laboratory abnormalities were hypoalbuminemia,lymphopenia,decreased percentage of lymphocytes (LYM) and neutrophils (NEU),elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH),and decreased CD8 count.The viral load of 2019-nCoV detected from patient respiratory tracts was positively linked to lung disease severity.ALB,LYM,LYM (%),LDH,NEU (%),and CRP were highly correlated to the acute lung injury.Age,viral load,lung injury score,and blood biochemistry indexes,albumin (ALB),CRP,LDH,LYM (%),LYM,and NEU (%),may be predictors of disease severity.Moreover,the Angiotensin Ⅱlevel in the plasma sample from 2019-nCoV infected patients was markedly elevated and linearly associated to viral load and lung injury.Our results suggest a number of potential diagnosis biomarkers and angiotensin receptor blocker (ARB) drugs for potential repurposing treatment of 2019-nCoV infection. | Yingxia Liu Yang Yang Cong Zhang Fengming Huang Fuxiang Wang Jing Yuan Zhaoqin Wang Jinxiu Li Jianming Li Cheng Feng Zheng Zhang Lifei Wang Ling Peng Li Chen Yuhao Qin Dandan Zhao Shuguang Tan Lu Yin Jun Xu Congzhao Zhou Chengyu Jiang Lei Liu | 2020 | Science China(Life Sciences)2020，63，3： | 157 |
| 2 | Future Physics Programme of BESⅢ显示文摘There has recently been a dramatic renewal of interest in hadron spectroscopy and charm physics. This renaissance has been driven in part by the discovery of a plethora of charmonium-like XYZ states at BESⅢ and B factories, and the observation of an intriguing proton-antiproton threshold enhancement and the possibly related X(1835) meson state at BESⅢ, as well as the threshold measurements of charm mesons and charm baryons. We present a detailed survey of the important topics in tau-charm physics and hadron physics that can be further explored at BESⅢ during the remaining operation period of BEPCⅡ. This survey will help in the optimization of the data-taking plan over the coming years, and provides physics motivation for the possible upgrade of BEPCⅡ to higher luminosity. | M.Ablikim M.N.Achasov P.Adlarson S.Ahmed M.Albrecht M.Alekseev A.Amoroso F.F.An Q.An Y.Bai O.Bakina R.Baldini Ferroli Y.Ban K.Begzsuren J.V.Bennett N.Berger M.Bertani D.Bettoni F.Bianchi J Biernat J.Bloms I.Boyko R.A.Briere L.Calibbi H.Cai X.Cai A.Calcaterra G.F.Cao N.Cao S.A.Cetin J.Chai J.F.Chang W.L.Chang J.Charles G.Chelkov Chen G.Chen H.S.Chen J.C.Chen M.L.Chen S.J.Chen Y.B.Chen H.Y.Cheng W.Cheng G.Cibinetto F.Cossio X.F.Cui H.L.Dai J.P.Dai X.C.Dai A.Dbeyssi D.Dedovich Z.Y.Deng A.Denig Denysenko M.Destefanis S.Descotes-Genon F.De Mori Y.Ding C.Dong J.Dong L.Y.Dong M.Y.Dong Z.L.Dou S.X.Du S.I.Eidelman J.Z.Fan J.Fang S.S.Fang Y.Fang R.Farinelli L.Fava F.Feldbauer G.Felici C.Q.Feng M.Fritsch C.D.Fu Y.Fu Q.Gao X.L.Gao Y.Gao Y.Gao Y.G.Gao Z.Gao B.Garillon I.Garzia E.M.Gersabeck A.Gilman K.Goetzen L.Gong W.X.Gong W.Gradl M.Greco L.M.Gu M.H.Gu Y.T.Gu A.Q.Guo F.K.Guo L.B.Guo R.P.Guo Y.P.Guo A.Guskov S.Han X.Q.Hao F.A.Harris K.L.He F.H.Heinsius T.Held Y.K.Heng Y.R.Hou Z.L.Hou H.M.Hu J.F.Hu T.Hu Y.Hu G.S.Huang J.S.Huang X.T.Huang X.Z.Huang Z.L.Huang N.Huesken T.Hussain W.Ikegami Andersson W.Imoehl M.Irshad Q.Ji Q.P.Ji X.B.Ji X.L.Ji H.L.Jiang X.S.Jiang X.Y.Jiang J.B.Jiao Z.Jiao D.P.Jin S.Jin Y.Jin T.Johansson N.Kalantar-Nayestanaki X.S.Kang R.Kappert M.Kavatsyuk B.C.Ke I.K.Keshk T.Khan A.Khoukaz P.Kiese R.Kiuchi R.Kliemt L.Koch O.B.Kolcu B.Kopf M.Kuemmel M.Kuessner A.Kupsc M.Kurth M.G.Kurth W.Kuhn J.S.Lange P.Larin L.Lavezzi H.Leithoff T.Lenz C.Li Cheng Li D.M.Li F.Li F.Y.Li G.Li H.B.Li H.J.Li J.C.Li J.W.Li Ke Li L.K.Li Lei Li P.L.Li P.R.Li Q.Y.Li W.D.Li W.G.Li X.H.Li X.L.Li X.N.Li X.Q.Li Z.B.Li H.Liang H.Liang Y.F.Liang Y.T.Liang G.R.Liao L.Z.Liao J.Libby C.X.Lin D.X.Lin Y.J.Lin B.Liu B.J.Liu C.X.Liu D.Liu D.Y.Liu F.H.Liu Fang Liu Feng Liu H.B.Liu H.M.Liu Huanhuan Liu Huihui Liu J.B.Liu J.Y.Liu K.Y.Liu Ke Liu Q.Liu S.B.Liu T.Liu X.Liu X.Y.Liu Y.B.Liu Z.A.Liu Zhiqing Liu Y.F.Long X.C.Lou H.J.Lu J.D.Lu J.G.Lu Y.Lu Y.P.Lu C.L.Luo M.X.Luo P.W.Luo T.Luo X.L.Luo S.Lusso X.R.Lyu F.C.Ma H.L.Ma L.L.Ma M.M.Ma Q.M.Ma X.N.Ma X.X.Ma X.Y.Ma Y.M.Ma F.E.Maas M.Maggiora S.Maldaner S.Malde Q.A.Malik A.Mangoni Y.J.Mao Z.P.Mao S.Marcello Z.X.Meng J.G.Messchendorp G.Mezzadri J.Min T.J.Min R.E.Mitchell X.H.Mo Y.J.Mo C.Morales Morales N.Yu.Muchnoi H.Muramatsu A.Mustafa S.Nakhoul Y.Nefedov F.Nerling I.B.Nikolaev Z.Ning S.Nisar S.L.Niu S.L.Olsen Q.Ouyang S.Pacetti Y.Pan M.Papenbrock P.Patteri M.Pelizaeus H.P.Peng K.Peters A.A.Petrov J.Pettersson J.L.Ping R.G.Ping A.Pitka R.Poling V.Prasad M.Qi T.Y.Qi S.Qian C.F.Qiao N.Qin X.P.Qin X.S.Qin Z.H.Qin J.F.Qiu S.Q.Qu K.H.Rashid C.F.Redmer M.Richter M.Ripka A.Rivetti V.Rodin M.Rolo G.Rong J.L.Rosner Ch.Rosner M.Rump A.Sarantsev M.Savrie K.Schoenning W.Shan X.Y.Shan M.Shao C.P.Shen P.X.Shen X.Y.Shen H.Y.Sheng X.Shi X.D Shi J.J.Song Q.Q.Song X.Y.Song S.Sosio C.Sowa S.Spataro F.F.Sui G.X.Sun J.F.Sun L.Sun S.S.Sun X.H.Sun Y.J.Sun Y.K Sun Y.Z.Sun Z.J.Sun Z.T.Sun Y.T Tan C.J.Tang G.Y.Tang X.Tang V.Thoren B.Tsednee I.Uman B.Wang B.L.Wang C.W.Wang D.Y.Wang H.H.Wang K.Wang L.L.Wang L.S.Wang M.Wang M.Z.Wang Wang Meng P.L.Wang R.M.Wang W.P.Wang X.Wang X.F.Wang X.L.Wang Y.Wang Y.F.Wang Z.Wang Z.G.Wang Z.Y.Wang Zongyuan Wang T.Weber D.H.Wei P.Weidenkaff H.W.Wen S.P.Wen U.Wiedner G.Wilkinson M.Wolke L.H.Wu L.J.Wu Z.Wu L.Xia Y.Xia S.Y.Xiao Y.J.Xiao Z.J.Xiao Y.G.Xie Y.H.Xie T.Y.Xing X.A.Xiong Q.L.Xiu G.F.Xu L.Xu Q.J.Xu W.Xu X.P.Xu F.Yan L.Yan W.B.Yan W.C.Yan Y.H.Yan H.J.Yang H.X.Yang L.Yang R.X.Yang S.L.Yang Y.H.Yang Y.X.Yang Yifan Yang Z.Q.Yang M.Ye M.H.Ye J.H.Yin Z.Y.You B.X.Yu C.X.Yu J.S.Yu C.Z.Yuan X.Q.Yuan Y.Yuan A.Yuncu A.A.Zafar Y.Zeng B.X.Zhang B.Y.Zhang C.C.Zhang D.H.Zhang H.H.Zhang H.Y.Zhang J.Zhang J.L.Zhang J.Q.Zhang J.W.Zhang J.Y.Zhang J.Z.Zhang K.Zhang L.Zhang S.F.Zhang T.J.Zhang X.Y.Zhang Y.Zhang Y.H.Zhang Y.T.Zhang Yang Zhang Yao Zhang Yi Zhang Yu Zhang Z.H.Zhang Z.P.Zhang Z.Q.Zhang Z.Y.Zhang G.Zhao J.W.Zhao J.Y.Zhao J.Z.Zhao Lei Zhao Ling Zhao M.G.Zhao Q.Zhao S.J.Zhao T.C.Zhao Y.B.Zhao Z.G.Zhao A.Zhemchugov B.Zheng J.P.Zheng Y.Zheng Y.H.Zheng B.Zhong L.Zhou L.P.Zhou Q.Zhou X.Zhou X.K.Zhou Xingyu Zhou Xiaoyu Zhou Xu Zhou A.N.Zhu J.Zhu J.Zhu K.Zhu K.J.Zhu S.H.Zhu W.J.Zhu X.L.Zhu Y.C.Zhu Y.S.Zhu Z.A.Zhu J.Zhuang B.S.Zou J.H.Zou 无 | 2020 | Chinese Physics C2020，44，4： | 517 |
| 3 | MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2显示文摘新兴的证据与肿瘤开发和前进显示出异常地表示的 microRNAs (miRNAs ) 的协会。然而,很少在胃的 carcinogenesis 对 miRNAs 的潜在的角色被知道。这里,我们执行了 miRNA microarray 屏蔽在配对的胃的癌症和他们的邻近的 nontumor 纸巾表示并且发现 miR-375 是的 miRNAs 差别极大地在胃的癌症纸巾的 downregulated。量的即时 PCR 分析证实那 miR-375 表情显著地从经历胃的切除术的病人与他们的 nontumor 对应物相比在超过 90% 主要胃的癌症被减少。miR-375 的 Overexpression 显著地在 vitro 并且在 vivo 禁止了胃的癌症房间增长。在胃的癌症房间的 miR-375 的强迫的表示显著地减少了 Janus kinase 的蛋白质水平 2 ( JAK2 )并且镇压带 JAK2 的 3 鈥? untranslated 区域的一个酶记者的活动,被预言的 miR-375-binding 地点的变化废除,显示那 JAK2 可以是 miR-375 目标基因。由由 RNAi 的 JAK2 的 AG490 或 silencing 的 JAK2 活动的任何一个抑制压制了类似于 miR-375 overexpression 的胃的癌症房间增长。而且, JAK2 的宫外的表示能部分颠倒 miR-375 引起的房间增长的抑制。最后,我们在胃的癌症发现了在 miR-375 表示和 JAK2 蛋白质水平之间的重要反的关联。因此,这些数据建议 miR-375 可以作为肿瘤 suppressor 工作由指向 JAK2 oncogene 潜在地调整胃的癌症房间增长,含有在胃的癌症的致病的 miR-375 的一个角色。 | Ling Ding Yanjun Xu Wei Zhang Yujie Deng Misi Si Ying Du Haomi Yao Xuyan Liu Yuehai Ke Jianmin Si Tianhua Zhou | 2010 | Cell Research2010，20，7： | 59 |
| 4 | 2018 Chinese Pediatric Cardiology Society(CPCS) guideline for diagnosis and treatment of syncope in children and adolescents显示文摘Syncope belongs to the transient loss of consciousness(TLOC), characterized by a rapid onset, short duration, and spontaneous complete recovery. It is common in children and adolescents, accounting for 1% to 2% of emergency department visits.Recurrent syncope can seriously affect children's physical and mental health, learning ability and quality of life and sometimes cardiac syncope even poses a risk of sudden death. The present guideline for the diagnosis and treatment of syncope in children and adolescents was developed for guiding a better clinical management of pediatric syncope. Based on the globally recent development and the evidence-based data in China, 2018 Chinese Pediatric Cardiology Society(CPCS) guideline for diagnosis and treatment of syncope in children and adolescents was jointly prepared by the Pediatric Cardiology Society, Chinese Pediatric Society, Chinese Medical Association(CMA)/Committee on Pediatric Syncope, Pediatricians Branch, Chinese Medical Doctor Association(CMDA)/Committee on Pediatric Cardiology, Chinese College of Cardiovascular Physicians, Chinese Medical Doctor Association(CMDA)/Pediatric Cardiology Society, Beijing Pediatric Society, Beijing Medical Association(BMA). The present guideline includes the underlying diseases of syncope in children and adolescents, the diagnostic procedures, methodology and clinical significance of standing test and headup tilt test, the clinical diagnosis vasovagal syncope, postural orthostatic tachycardia syndrome, orthostatic hypotension and orthostatic hypertension, and the treatment of syncope as well as follow-up. | Cheng Wang Yaqi Li Ying Liao Hong Tian Min Huang Xiangyu Dong Lin Shi Jinghui Sun Hongfang Jin Junbao Du Jindou An Jie Chen Mingwu Chen Qi Chen Sun Chen Yonghong Chen Zhi Chen Adolphus Kai-tung Chau Junbao Du Zhongdong Du Junkai Duan Hongyu Duan Xiangyu Dong Lin Feng Lijun Fu Fangqi Gong Yonghao Gui Ling Han Zhenhui Han Bing He Zhixu He Xiufen Hu Yimin Hua Guoying Huang Min Huang Ping Huang Yujuan Huang Hongfang Jin Mei Jin Bo Li Fen Li Tao Li Xiaohui Li Xiaoyan Liu Yan Li Haitao Lv Tiewei Lv Zipu Li Luyi Ma Silin Pan Yusheng Pang Hua Peng Yuming Qin Jie Shen Lin Shi Kun Sun Jinghui Sun Hong Tian Jie Tian Cheng Wang Hong Wang Lei Wang Jinju Wang Wendi Wang Yuli Wang Rongzhou Wu Tianhe Xia Yanyan Xiao Chunhong Xie Yanlin Xing Zhenyu Xiong Baoyuan Xu Yi Xu Hui Yan Shiwei Yang Qijian Yi Xia Yu Xianyi Yu Yue Yuan Hongyan Zhang Huili Zhang Li Zhang Qingyou Zhang Xi Zhang Yanmin Zhang Zhiwei Zhang Cuifen Zhao Bin Zhou Hua Zhu | 2018 | Science Bulletin2018，63，23： | 54 |
| 5 | Service-aware 6G:An intelligent and open network based on the convergence of communication,computing and caching显示文摘With the proliferation of the Internet of Things(IoT),various services are emerging with totally different features and requirements,which cannot be supported by the current fifth generation of mobile cellular networks(5G).The future sixth generation of mobile cellular networks(6G)is expected to have the capability to support new and unknown services with changing requirements.Hence,in addition to enhancing its capability by 10–100 times compared with 5G,6G should also be intelligent and open to adapt to the ever-changing services in the IoT,which requires a convergence of Communication,Computing and Caching(3C).Based on the analysis of the requirements of new services for 6G,this paper identifies key enabling technologies for an intelligent and open 6G network,all featured with 3C convergence.These technologies cover fundamental and emerging topics,including 3C-based spectrum management,radio channel construction,delay-aware transmission,wireless distributed computing,and network self-evolution.From the detailed analysis of these 3C-based technologies presented in this paper,we can see that although they are promising to enable an intelligent and open 6G,more efforts are needed to realize the expected 6G network. | Yiqing Zhou Ling Liu Lu Wang Ning Hui Xinyu Cui Jie Wu Yan Peng Yanli Qi Chengwen Xing | 2020 | Digital Communications and Networks2020，6，3： | 57 |
| 6 | Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial显示文摘BACKGROUND: Disease recurrence is a main challenge in treatment of hepatocellular carcinoma (HCC). There is no generally accepted method for preventing recurrence of HCC after resection. OBJECTIVE: To compare the efficacy of a traditional herbal medicine (THM) regimen and transarterial chemoembolization (TACE) in preventing recurrence in post-resection patients with small HCC. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This is a multicenter, open-label, randomized, controlled study, which was undertaken in five centers of China. A total of 379 patients who met the eligibility criteria and underwent randomization were enrolled in this trial. One hundred and eighty-eight patients were assigned to the THM group and received Cinobufacini injection and Jiedu Granule, and the other 191 patients were assigned to the TACE group and received one single course of TACE. MAIN OUTCOME MEASURES: Primary outcome measures were the annual recurrence rate and the time to recurrence. Incidence of adverse events was regarded as the secondary outcome measure. RESULTS: Among the 364 patients who were included in the intention-to-treat analysis, 67 patients of the THM group and 87 of the TACE group had recurrence, with a hazard ratio of 0.695 (P = 0.048). Median recurrence-free survival of the patients in the THM and TACE groups was 46.89 and 34.49 months, respectively. Recurrence rates at 1, 2 and 3 years were 17.7%, 33.0% and 43.5% for the THM group, and 28.8%, 42.5% and 54.0% for the TACE group, respectively (P = 0.026). Multivariate analysis indicated that the THM regimen had a big advantage for prolonging the recurrence-free survival. Adverse events were mild and abnormality of laboratory indices of the two groups were similar. CONCLUSION: In comparison with TACE therapy, the THM regimen was associated with diminished risk of recurrence of small-sized HCC after resection, with comparable adverse events. TRIAL REGISTRTION IDENTIFIER: This trial was registered in the Chinese Clinical Trial Registry with the identifier ChiCTR-TRC-07000033. | Xiao-feng Zhai Zhe Chen Bai Li Feng Shen Jia Fan Wei-ping Zhou Yun-ke Yang Jing Xu Xiao Qin Le-qun Li Chang-quan Ling | 2013 | Journal of Integrative Medicine2013，11，2： | 49 |
| 7 | Mortality and Morbidity of Extremely Low Birth Weight Infants in the Mainland of China: A Multi-center Study显示文摘 | Hui-Jia Lin Li-Zhong Du Xiao-Lu Ma Li-Ping Shi Jia-Hua Pan Xiao-Mei Tong Qiu-Ping Li Jian-Guo Zhou Bing Yi Ling Liu Yun-Bing Chen Qiu-Fen Wei Hui-Qing Wu Mei Li Cui-Qing Li Xi-Rong Gao Shi-Wen Xia Wen-Bin Li Chao-Ying Ya Ling He Kun Liang Xiao-Yu Zhou Shu-Ping Han Qin Lyu Yin-Ping Qiu Wen Li Dong-Mei Chen Hong-Ru Lu Xiao-Hong Liu Hong Liu Zhen-Lang Lin Li Liu Jia-Jun Zhu Hong Xiong Shao-Jie Yue Si-Qi Zhuang | 2015 | Chinese Medical Journal2015，，20： | 49 |
| 8 | Effects of dietary supplementation of probiotic,Clostridium butyricum,on growth performance,immune response,intestinal barrier function,and digestive enzyme activity in broiler chickens challenged with Escherichia coli K88显示文摘Background:Colibacillosis caused by enterotoxigenic Escherichia coli(E.coli) results in economic losses in the poultry industry.Antibiotics are usually used to control colibacillosis,however,E.coli has varying degrees of resistance to different antibiotics.Therefore the use of probiotics is becoming accepted as an alternative to antibiotics.In this study,we evaluated the effects of Clostridium butyricum(C.butyricum) on growth performance,immune response,intestinal barrier function,and digestive enzyme activity in broiler chickens challenged with Escherichia coli(E.coif) K88.Methods:The chickens were randomly divided into four treatment groups for 28 days.Negative control treatment(NC) consisted of birds fed a basal diet without E.coli K88 challenge and positive control treatment(PC) consisted of birds fed a basal diet and challenged with E.coli K88.C.butyricum probiotic treatment(CB) consisted of birds fed a diet containing 2×10~7 cfu C butyricum/kg of diet and challenged with E.coli K88.Colistin sulfate antibiotic treatment(CS)consisted of birds fed a diet containing 20 mg colistin sulfate/kg of diet and challenged with E.coli K88.Results:The body weight(BW) and average day gain(ADG) in the broilers of CB group were higher(P< 0.05) than the broilers in the PC group overall except the ADG in the 14-21 d post-challenge.The birds in CB treatment had higher(P < 0.05) concentration of tumor necrosis factor-α(TNF-α) at 3 and 7 d post-challenge,and higher(P < 0.05)concentration of interleukin-4(IL-4) at 14 d post-challenge than those in the PC treatment group.The concentration of serum endotoxin in CB birds was lower(P<0.05) at 21 d post-challenge,and the concentrations of serum diamine oxidase in CB birds were lower(P < 0.05) at 14 and 21 d post-challenge than in PC birds.Birds in CB treatment group had higher(P< 0.05) jejunum villi height than those in PC,NC,or CS treatment at 7,14,and 21 d post-challenge.In comparison to PC birds,the CB birds had lower(P < 0.05) jejunum crypt depth during the whole experiment.The birds in CB or CS treatment group had higher(P < 0.05) activities of amylase and protease at 3,7,and 14 d post-challenge,and higher(P< 0.05) activity of lipase at 3,7 d post-challenge than PC birds.Conclusions:In all,these results indicate that dietary supplementation with C.butyricum promotes immune response,improves intestinal barrier function,and digestive enzyme activities in broiler chickens challenged with E.coli K88.There is no significant difference between the C.butyricum probiotic treatment and the colistin sulfate antibiotic treatment.Therefore,the C.butyricum probiotic may be an alternative to antibiotic for broiler chickens. | Ling Zhang Lingling Zhang Xiu'an Zhan Xinfu Zeng Lin Zhou Guangtian Cao An'guo Chen Caimei Yang | 2016 | Journal of Animal Science and Biotechnology2016，7，1： | 43 |
| 9 | The Genome of Artemisia annua Provides Insight into the Evolution of Asteraceae Family and Artemisinin Biosynthesis显示文摘Artemisia annua,通常已知的同样香甜的苦恼或 Qinghao,是到中国的一个灌木土著人并且长被用于药用的目的。A。annua 现在作为有势力抗疟药混合物的唯一的生来的来源全球性被栽培, artemisinin。这里,我们报导 A 的 1.74-gigabase 染色体的一个高质量的草稿集会。annua,高度异质接合,富于重复定序,并且包含 63 ? 226 编码蛋白质的基因,在定序的植物种类之中的最大的数字之一。我们发现了那,作为在 Asteraceae 的一些定序的染色体之一, A。annua 染色体包含对这大被子植物 clade 特定的很多基因。尤其是,扩大和编码涉及萜烯生合成的酶的基因的功能的多样化与 artemisinin biosynthetic 小径的进化一致。我们进一步由介绍那 A 的 transcriptome 揭示了。annua 发展了复杂 transcriptional 规章的网络位于 \O 下面 artemisinin 生合成。把转基因的 A 基于我们产生了的全面 genomic 和 transcriptomic 分析。artemisinin 高级的生产的 annua 线,它现在为大规模生产准备好了并且将从而帮助遇见增加 artemisinin 的全球需求的挑战。 | Qian Shen Lida Zhang Zhihua Liao Shengyue Wang Tingxiang Yan Pu Shi Meng Liu Xueqing Fu Qifang Pan Yuliang Wang Zongyou Lv Xu Lu Fangyuan Zhang Weimin Jiang Yanan Ma Minghui Chen Xiaolong Hao Ling Li Yueli Tang Gang Lv Yan Zhou Xiaofen Sun Peter E. Brodelius Jocelyn K.C. Rose Kexuan Tang | 2018 | Molecular Plant2018，11，6： | 47 |
| 10 | TGF-β signaling in cancer metastasis显示文摘转变生长因素(TGF )- 发信号的事件是众所周知的控制多样的进程和众多的回答例如房间增长,区别, apoptosis,和移植。在癌症的 TGF- 发信号戏上下文依赖者角色:在 pre 恶意的房间, TGF- 首先作为肿瘤 suppressor 工作,当在癌症的以后的阶段发信号的 TGF- 支持侵略和转移时。最近的研究也建议了在 TGF- 发信号和另外的发信号的小径之间的串音例如河马, Wnt, EGFR/RAS,和 PI3K/AKT 小径,可以实质地贡献我们 TGF- 发信号和癌症的当前的理解。由于 TGF- 的广阔效果, TGF- 和它的下游的发信号部件的封锁提供多重治疗学的机会。因此,为为众多的疾病表明治疗的 anti-TGF- 的眼界显得明亮并且将提供珍贵信息并且想在这药上分子的设计。在这评论,我们集中于最近的卓见进在可以贡献新奇指向癌症的治疗的发展的癌症转移发信号的 TGF- 的规定。 | Feng Xie Li Ling Hans van Dam Fangfang Zhou Long Zhang | 2018 | Acta Biochimica et Biophysica Sinica2018，50，1： | 36 |
| 11 | Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine显示文摘Traditional Chinese medicine(TCM) is an important part of the treatment of primary liver cancer(PLC) in China; however, the current instructions for the integrative use of traditional Chinese and Western medicine for PLC are mostly based on expert opinion. There is no evidence-based guideline for clinical practice in this field. Therefore, the Shanghai Association of Chinese Integrative Medicine has established amultidisciplinary working group to develop this guideline, which focuses on the most important questions about the use of TCM during PLC treatment. This guideline was developed following the methodological process recommended by the World Health Organization Handbook for Guideline Development.Two rounds of questionnaire survey were performed to identify clinical questions; published evidence was searched; the Grading of Recommendations Assessment, Development and Evaluation approach was used to evaluate the body of evidence; and recommendations were formulated by combining the quality of evidence, patient preferences and values, and other risk factors. The guideline was written based on the Reporting Items for Practice Guidelines in Healthcare tool. This guideline contains 10 recommendations related to 8 questions, including recommendations for early treatment by TCM after surgery, TCM combined with transcatheter arterial chemoembolization for advanced PLC, TCM drugs for external use, and acupuncture and moxibustion therapy. | Chang-quan Ling Jia Fan Hong-sheng Lin Feng Shen Zhen-ye Xu Li-zhu Lin Shu-kui Qin Wei-ping Zhou Xiao-feng Zhai Bai Li Qing-hui Zhou | 2018 | Journal of Integrative Medicine2018，16，4： | 38 |
| 12 | China National Medical Products Administration approval summary:anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy显示文摘Background:On May 8,2018,the China National Medical Products Administration(NMPA)approved anlotinib,an orally administered anti-angiogenesis inhibitor,for the treatment of patients with advanced non-small cell lung can-cer(NSCLC)who have progressed after treatment with two or more lines of prior systemic chemotherapy.Main body of the abstract:China NMPA reviewed and inspected a regional double-blinded,placebo-controlled,Phase III trial comparing the overall survival(OS)of NSCLC patients between the anlotinib and placebo arms.A total of 437 patients were randomized(2:1)to receive either anlotinib(n=294)or placebo(n=143)once daily on a 2-week on and 1-week off schedule.Patients with epidermal growth factor receptor(EGFR)or activating anaplastic lymphoma kinase(ALK)genomic tumor aberrations should have disease progression on NMPA-approved therapy.Anlotinib is the first NMPA-approved drug for patients with advanced NSCLC who have progressed on at least two lines of prior systemic chemotherapies in China.The approval was based on a statistically and clinically significant improvement in median OS with anlotinib(9.46 months)compared with placebo[6.37 months;hazard ratio(HR])=0.70,95%confidence interval(CI)=0.55-0.89;two-sided log-rank P=0.002].The confirmed objective response rate(ORR)was 9.2%in the anlotinib arm and 0.7%in the placebo arm.The median duration of response(DoR)was 4.83 months,with a 95%CI of 3.31-6.97 months.The toxicity profile of anlotinib was consistent with that of known anti-angiogenesis inhibitors.Common adverse drug reactions(ADRs)in anlotinib-treated patients included hypertension(67.4%),hand-foot syndrome(43.9%),hemoptysis(14.0%),thyroid stimulating hormone(TSH)elevation(46.6%),and corrected QT interval(QTc)prolongation(26.2%).Short conclusion:Anlotinib demonstrated a clinically significant OS prolongation as a novel therapeutic option for advanced or metastatic NSCLC following at least two lines of chemotherapy. | Ming Zhou Xiaoyuan Chen Hong Zhang Lin Xia Xin Tong Limin Zou Ruimin Hao Jianhong Pan Xiao Zhao Dongmei Chen Yuanyuan Song Yueli Qi Ling Tang Zhifang Liu Rong Gao Yuankai Shi Zhimin Yang | 2019 | Cancer Communications2019，39，1： | 35 |
| 13 | Analysis of pesticide residues in commercially available chenpi using a modified QuEChERS method and GC-MS/MS determination显示文摘To ensure the safety of the commercially available chenpi,a convenient and fast analytical method was developed for the determination of 133 pesticide residues in chenpi using gas chromatography-tandem mass spectrometry(GC-MS/MS).In this study,different extraction solvents,redissolution solvents and adsorbents were tested according to the recovery and purification effect to obtain a modified QuEChERS method.The samples were extracted with acetonitrile.During the clean-up step,octadecyl-modified silica(C18)and graphitized carbon black(GCB)were selected,and aminopropyl(NH2)was used instead of primary secondary amine(PSA)because of its weaker ion exchange capacity which had little effect on the recovery of ditalimfos.Samples were quantified by matrix-matched calibration with internal standards.All pesticides showed good linearity in the respective range,both with values of r2>0.99.The average recoveries of the pesticides spiked samples ranged from 70.0% to 112.2% with the RSDs of 0.2%–14.4%.The modified QuEChERS method was validated and applied to twenty real samples.Five pesticides were found in eight batches,but no pesticide exceeded the maximum residue limits(MRL,MRL reference to European commission). | Shuang Li Peipei Yu Ceng Zhou Ling Tong Dongxiang Li Zhiguo Yu Yunli Zhao | 2020 | Journal of Pharmaceutical Analysis2020，10，1： | 34 |
| 14 | Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease显示文摘Background Since early December 2019,the 2019 novel coronavirus disease(COVID-19)has caused pneumonia epidemic in Wuhan,Hubei province of China.This study aimed to investigate the factors affecting the progression of pneumonia in COVID-19 patients.Associated results will be used to evaluate the prognosis and to find the optimal treatment regimens for COVID-19 pneumonia.Methods Patients tested positive for the COVID-19 based on nucleic acid detection were included in this study.Patients were admitted to 3 tertiary hospitals in Wuhan between December 30,2019,and January 15,2020.Individual data,laboratory indices,imaging characteristics,and clinical data were collected,and statistical analysis was performed.Based on clinical typing results,the patients were divided into a progression group or an improvement/stabilization group.Continuous variables were analyzed using independent samples t-test or Mann-Whitney U test.Categorical variables were analyzed using Chi-squared test or Fisher’s exact test.Logistic regression analysis was performed to explore the risk factors for disease progression.Results Seventy-eight patients with COVID-19-induced pneumonia met the inclusion criteria and were included in this study.Efficacy evaluation at 2 weeks after hospitalization indicated that 11 patients(14.1%)had deteriorated,and 67 patients(85.9%)had improved/stabilized.The patients in the progression group were significantly older than those in the disease improvement/stabilization group(66[51,70]vs.37[32,41]years,U=4.932,P=0.001).The progression group had a significantly higher proportion of patients with a history of smoking than the improvement/stabilization group(27.3%vs.3.0%,χ^2=9.291,P=0.018).For all the 78 patients,fever was the most common initial symptom,and the maximum body temperature at admission was significantly higher in the progression group than in the improvement/stabilization group(38.2[37.8,38.6]vs.37.5[37.0,38.4]°C,U=2.057,P=0.027).Moreover,the proportion of patients with respiratory failure(54.5%vs.20.9%,χ^2=5.611,P=0.028)and respiratory rate(34[18,48]vs.24[16,60]breaths/min,U=4.030,P=0.004)were significantly higher in the progression group than in the improvement/stabilization group.C-reactive protein was significantly elevated in the progression group compared to the improvement/stabilization group(38.9[14.3,64.8]vs.10.6[1.9,33.1]mg/L,U=1.315,P=0.024).Albumin was significantly lower in the progression group than in the improvement/stabilization group(36.62±6.60 vs.41.27±4.55 g/L,U=2.843,P=0.006).Patients in the progression group were more likely to receive high-level respiratory support than in the improvement/stabilization group(χ^2=16.01,P=0.001).Multivariate logistic analysis indicated that age(odds ratio[OR],8.546;95%confidence interval[CI]:1.628-44.864;P=0.011),history of smoking(OR,14.285;95%CI:1.577-25.000;P=0.018),maximum body temperature at admission(OR,8.999;95%CI:1.036-78.147,P=0.046),respiratory failure(OR,8.772,95%CI:1.942-40.000;P=0.016),albumin(OR,7.353,95%CI:1.098-50.000;P=0.003),and C-reactive protein(OR,10.530;95%CI:1.224-34.701,P=0.028)were risk factors for disease progression.Conclusions Several factors that led to the progression of COVID-19 pneumonia were identified,including age,history of smoking,maximum body temperature at admission,respiratory failure,albumin,and C-reactive protein.These results can be used to further enhance the ability of management of COVID-19 pneumonia. | Wei Liu Zhao-Wu Tao Lei Wang Ming-Li Yuan Kui Liu Ling Zhou Shuang Wei Yan Deng Jing Liu Hui-Guo Liu Ming Yang Yi Hu | 2020 | Chinese Medical Journal2020，，9： | 31 |
| 15 | The recognizing of ca. 1.95 Ga tectono-thermal eventin Kong-ling nucleus and its significance for the evolution of Yangtze Block, South China显示文摘Some 1.95 Ga metamorphism of high-grade Ar-chean rocks in Kongling terrain, continental nucleus of Yangtze Block, South China, are recognized by Sm-Nd dating. This event is further confirmed by the ages of single zircon SHRIMP U-Pb and K-Ar analyses of TTG and (or) paragneisses, and intrusions of potassic-granitic batholith in the region. The coincidence in period between the high-grade metamorphism in the Kongling area and the creation of major basement rocks of its neighborhoods of the Yangtze Block around the Kongling Archean nucleus makes it a favorable explanation for their tectonic connections that, in the whole Yangtze Block there was some tectono-thermal event of ca. 2.0-1.8 Ga, which resulted in the formation of unitive Yangtze basement. | LING Wenli GAO Shan ZHANG Benren ZHOU Lian XU Qidong | 2001 | Chinese Science Bulletin2001，46，4： | 29 |
| 16 | Type Ⅰ and type Ⅱ Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area显示文摘BACKGROUND Type I Helicobacter pylori(H.pylori)infection causes severe gastric inflammation and is a predisposing factor for gastric carcinogenesis.However,its infection status in stepwise gastric disease progression in this gastric cancer prevalent area has not been evaluated;it is also not known its impact on commonly used epidemiological gastric cancer risk markers such as gastrin-17(G-17)and pepsinogens(PGs)during clinical practice.AIM To explore the prevalence of type I and type II H.pylori infection status and their impact on G-17 and PG levels in clinical practice.METHODS Thirty-five hundred and seventy-two hospital admitted patients with upper gastrointestinal symptoms were examined,and 523 patients were enrolled in this study.H.pylori infection was confirmed by both 13C-urea breath test and serological assay.Patients were divided into non-atrophic gastritis(NAG),nonatrophic gastritis with erosion(NAGE),chronic atrophic gastritis(CAG),peptic ulcers(PU)and gastric cancer(GC)groups.Their serological G-17,PG I and PG II values and PG I/PG II ratio were also measured.RESULTS A total H.pylori infection rate of 3572 examined patients was 75.9%,the infection rate of 523 enrolled patients was 76.9%,among which type I H.pylori infection accounted for 72.4%(291/402)and type II was 27.6%;88.4%of GC patients were H.pylori positive,and 84.2%of them were type I infection,only 11.6%of GC patients were H.pylori negative.Infection rates of type I H.pylori in NAG,NAGE,CAG,PU and GC groups were 67.9%,62.7%,79.7%,77.6%and 84.2%,respectively.H.pylori infection resulted in significantly higher G-17 and PG II values and decreased PG I/PG II ratio.Both types of H.pylori induced higher G-17 level,but type I strain infection resulted in an increased PG II level and decreased PG I/PG II ratio in NAG,NAGE and CAG groups over uninfected controls.Overall PG I levels showed no difference among all disease groups and in the presence or absence of H.pylori;in stratified analysis,its level was increased in GC and PU patients in H.pylori and type I H.pylori-positive groups.CONCLUSION Type I H.pylori infection is the major form of infection in this geographic region,and a very low percentage(11.6%)of GC patients are not infected by H.pylori.Both types of H.pylori induce an increase in G-17 level,while type I H.pylori is the major strain that affects PG I and PG IIs level and PG I/PG II ratio in stepwise chronic gastric disease.The data provide insights into H.pylori infection status and indicate the necessity and urgency for bacteria eradication and disease prevention in clinical practice. | Lin Yuan Jun-Bo Zhao Ying-Lei Zhou Ya-Bin Qi Qiong-Ya Guo Hai-Hui Zhang Muhammad Noman Khan Ling Lan Chang-He Jia Yan-Rui Zhang Song-Ze Ding | 2020 | World Journal of Gastroenterology2020，26，25： | 29 |
| 17 | Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan,China:a retrospective study显示文摘Background:The 2019 novel coronavirus has caused the outbreak of the acute respiratory disease in Wuhan,Hubei Province of China since December 2019.This study was performed to analyze the clinical characteristics of patients who succumbed to and who recovered from 2019 novel coronavirus disease(COVID-19).Methods:Clinical data were collected from two tertiary hospitals in Wuhan.A retrospective investigation was conducted to analyze the clinical characteristics of fatal cases of COVID-19(death group)and we compare them with recovered patients(recovered group).Continuous variables were analyzed using the Mann-WhitneyU test.Categorical variables were analyzed byχ2 test or Fisher exact test as appropriate.Results:Our study enrolled 109 COVID-19 patients who died during hospitalization and 116 recovered patients.The median age of the death group was older than the recovered group(69[62,74]vs.40[33,57]years,Z=9.738,P<0.001).More patients in the death group had underlying diseases(72.5%vs.41.4%,χ2=22.105,P<0.001).Patients in the death group had a significantly longer time of illness onset to hospitalization(10.0[6.5,12.0]vs.7.0[5.0,10.0]days,Z=3.216,P=0.001).On admission,the proportions of patients with symptoms of dyspnea(70.6%vs.19.0%,χ2=60.905,P<0.001)and expectoration(32.1%vs.12.1%,χ2=13.250,P<0.001)were significantly higher in the death group.The blood oxygen saturation was significantly lower in the death group(85[77,91]%vs.97[95,98]%,Z=10.625,P<0.001).The white blood cell(WBC)in death group was significantly higher on admission(7.23[4.87,11.17]vs.4.52[3.62,5.88]×109/L,Z=7.618,P<0.001).Patients in the death group exhibited significantly lower lymphocyte count(0.63[0.40,0.79]vs.1.00[0.72,1.27]×109/L,Z=8.037,P<0.001)and lymphocyte percentage(7.10[4.45,12.73]%vs.23.50[15.27,31.25]%,Z=10.315,P<0.001)on admission,and the lymphocyte percentage continued to decrease during hospitalization(7.10[4.45,12.73]%vs.2.91[1.79,6.13]%,Z=5.242,P<0.001).Alanine transaminase(22.00[15.00,34.00]vs.18.70[13.00,30.38]U/L,Z=2.592,P=0.010),aspartate transaminase(34.00[27.00,47.00]vs.22.00[17.65,31.75]U/L,Z=7.308,P<0.001),and creatinine levels(89.00[72.00,133.50]vs.65.00[54.60,78.75]μmol/L,Z=6.478,P<0.001)were significantly higher in the death group than those in the recovered group.C-reactive protein(CRP)levels were also significantly higher in the death group on admission(109.25[35.00,170.28]vs.3.22[1.04,21.80]mg/L,Z=10.206,P<0.001)and showed no significant improvement after treatment(109.25[35.00,170.28]vs.81.60[27.23,179.08]mg/L,Z=1.219,P=0.233).The patients in the death group had more complications such as acute respiratory distress syndrome(ARDS)(89.9%vs.8.6%,χ2=148.105,P<0.001),acute cardiac injury(59.6%vs.0.9%,χ2=93.222,P<0.001),acute kidney injury(18.3%vs.0%,χ2=23.257,P<0.001),shock(11.9%vs.0%,χ2=14.618,P<0.001),and disseminated intravascular coagulation(DIC)(6.4%vs.0%,χ2=7.655,P=0.006).Conclusions:Compared to the recovered group,more patients in the death group exhibited characteristics of advanced age,pre-existing comorbidities,dyspnea,oxygen saturation decrease,increased WBC count,decreased lymphocytes,and elevated CRP levels.More patients in the death group had complications such as ARDS,acute cardiac injury,acute kidney injury,shock,and DIC. | Yan Deng Wei Liu Kui Liu Yuan-Yuan Fang Jin Shang Ling Zhou Ke Wang Fan Leng Shuang Wei Lei Chen Hui-Guo Liu | 2020 | Chinese Medical Journal2020，，11： | 29 |
| 18 | Urinary trypsin inhibitor attenuates hepatic ischemia-reperfusion injury by reducing nuclear factor-kappa B activation显示文摘BACKGROUND:Urinary trypsin inhibitor(UTI)inhibits the inflammatory response and protects against ischemia- reperfusion(I/R)injury.The inflammatory response is mediated by nuclear factor-kappa B(NF-κB)and its related target genes and products such as vascular endothelial cell adhesion molecule and CXC chemokines.We aimed to assess the roles of those mediators in a UTI-treated mouse model of hepatic I/R injury. METHODS:Treatment group 1(UTI given 5 minutes prior to liver ischemia),treatment group 2(UTI given 5 minutes after the anhepatic phase)and a control group were investigated.Blood and liver samples were obtained and compared at 1,3,6 and 24 hours after reperfusion. RESULTS:Attenuation of pathological hepatocellular damage was greater in the treatment groups than in the control group(P<0.05).Compared with the control group, the UTI treatment groups showed significantly lower serum alanine aminotransferase and aspartate aminotransferase levels,decreased myeloperoxidase activity,and reduced NF- κB activation.Also downregulated was the expression of tumor necrosis factor-alpha,cytokine-induced neutrophil chemoattractant,and macrophage inflammatory protein-2 at the mRNA level.P-selectin protein and intercellular adhesion molecule-1 protein expression were also downregulated.In addition,the treatment group 1 showed a better protective effect against I/R injury than the treatment group 2.CONCLUSIONS:UTI reduces NF-κB activation and downregulates the expression of its related mediators, followed by the inhibition of neutrophil aggregation and infiltration in hepatic I/R injury.The protective role of UTI is more effective in prevention than in treatment. | Wu, Yi-Jun Ling, Qi Zhou, Xin-Hui Wang, Yan Xie, Hai-Yang Yu, Ji-Ren Zheng, Shu-Sen | 2009 | Hepatobiliary & Pancreatic Diseases International2009，8，1： | 28 |
| 19 | Extracellular heat-shock protein 70 aggravates cerulein-induced pancreatitis through toll-like receptor-4 in mice显示文摘在受不了尖锐胰腺炎的病人,的背景致病完全没被理解,并且在 vitro 的几最近的研究建议热吃惊蛋白质可能在房间发信号起一个重要作用。在胰腺炎调查细胞外的热吃惊蛋白质 70 的可能的角色( Hsp70 ),像使用费的 receptor-4 ( TLR4 )缺乏、野类型的老鼠在 导致cerulein 的胰腺炎( CIP )的功课期间与外长的 Hsp70 被管理 .Methods 尖锐胰腺炎被 cerulein 的 5 intraperitoneal 注射导致在时时间隔,然后通过尾的静脉与 recombinant 对待 Hsp70 在 cerulein 注射的开始以后的 4 个小时。随后,浆液淀粉酶和浆液 cytokines 层次被检测。胰的 Histologic 改变被评估。肿瘤坏死因素 alpha (TNF -- 一) 集中和 myeloperoxidase (军邮局) 在胰和肺的活动被分析。在胰腺的织物的原子因素 kappa B ( NF-KB )激活在 CIP 与 recombinant Hsp70 用一个敏感 RelA 连接酶的 immunosorbent assay.Results 处理被测量到野类型的老鼠在胰导致了发炎的重要恶化,浆液 cytokines 的提高的层次,肺的军邮局活动的起来规定和肺纸巾TNF-集中的增加。相反,有到TLR4缺乏的老鼠的 Hsp70 的处理在浆液 cytokines 层次上有小效果,胰腺的发炎,肺的军邮局活动和 TNF -- concentrations.Conclusions 结果建议细胞外的 HspTO 可能导致全身的煽动性的反应没有感染,在 vivo 和 TLR4 的症候群(先生) -Iike 反应可能在 CIP 的前进涉及煽动性的反应的 调停Hsp70 的激活。 | SONG Jun-min LIU Hong-xiang LI Yuan ZENG Yu-jian ZHOU Zong-guang LIU Hai-yi XU Bing WANG Ling ZHOU Bin WANG Rong | 2008 | Chinese Medical Journal2008，，15： | 27 |
| 20 | Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China:a hospital.based,multicenter,cross-sectional survey显示文摘Background: The increasing prevalence of colorectal cancer(CRC) in China and the paucity of information about relevant expenditure highlight the necessity of better understanding the financial burden and effect of CRC diagnosis and treatment. We performed a survey to quantify the direct medical and non-medical expenditure as well as the resulting financial burden of CRC patients in China.Methods: We conducted a multicenter, cross-sectional survey in 37 tertiary hospitals in 13 provinces across China between 2012 and 2014. Each enrolled patient was interviewed using a structured questionnaire. All expenditure data were inflated to the 2014 Chinese Yuan(CNY; 1 CNY = 0.163 USD). We quantified the overall expenditure and financial burden and by subgroup(hospital type, age at diagnosis, sex, education, occupation, insurance type, household income, clinical stage, pathologic type, and therapeutic regimen). We then performed generalized linear modeling to determine the factors associated with overall expenditure.Results: A total of 2356 patients with a mean age of 57.4 years were included, 57.1 % of whom were men; 13.9% of patients had stage I cancer; and the average previous-year household income was 54,525 CNY.The overall average direct expenditure per patient was estimated to be 67,408 CNY, and the expenditures for stage Ⅰ, Ⅱ, Ⅲ, and Ⅳ disease were 56,099 CNY, 59,952 CNY, 67,292 CNY, and 82,729 CNY, respectively. Non-medical expenditure accounted for 8.3%of the overall expenditure. The 1-year out-of-pocket expenditure of a newly diagnosed patient was 32,649 CNY, which accounted for 59.9% of their previous-year household income and caused 75.0% of families to suffer an unmanageable financial burden. Univariate analysis showed that financial burden and overall expenditure differed in almost all subgroups(P < 0.05), except for sex. Multivariate analysis showed that patients who were treated in specialized hospitals and those who were diagnosed with adenocarcinoma or diagnosed at a later stage were likely to spend more,whereas those with a lower household income and those who underwent surgery spent less(all P < 0.05).Conclusions: For patients in China, direct expenditure for the diagnosis and treatment of CRC seemed catastrophic,and non-medical expenditure was non-ignorable. The financial burden varied among subgroups, especially among patients with different clinical stages of disease, which suggests that, in China, CRC screening might be cost-effective. | Hui-Yao Huang Ju-Fang Shi Lan-Wei Guo Ya-Na Bai Xian-Zhen Liao Guo-iangLiu A-Yan Mao Jian-Song Ren Xiao-Jie Sun Xin-Yu Zhu Le Wang Bing-Bing Song Ling-Bin Du Lin Zhu Ji-Yong Gong Qi Zhou Yu-Qin Liu Rong Cao Ling Mai Li Lan Xiao-Hua Sun Ying Ren Jin-Yi Zhou Yuan-Zheng Wang Xiao Qi Pei-An Lou Dian Shi Ni Li Kai Zhang Jie He Min Dai | 2017 | Chinese Journal of Cancer2017，36，8： | 25 |
您所在的机构暂未开通此部分的功能，请联系管理员